Moleculin Biotech, Inc. · NASDAQ:MBRX
Moleculin Biotech — Corporate Update (November 2022)
15 slides from Moleculin Biotech's corporate update, Nov 14, 2022
Slide 1: Moleculin
-<S}MOLECULIN We is e-
Slide 2: Disclaimer
Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,”
Slide 3: Better Treatments, More Tomorrows
Better Treatments, More Tomorrows Advancing growing pij of clinical programs fo! treatment of highly re «aw cancers and viruses movecutin é a q —_—
Slide 4: Third Quarter 2022 Noteworthy Evolution of the Company
Third Quarter 2022 Three Phase 1b/2 clinical studies with enrollment N ote WO rt hy or dosing now underway for Annamycin 3 Evolution of Report from independent cardiology expert continues to confirm no evidence of cardiotoxicity associated with Annamycin the Company Multiple milestones and key data
Slide 5: Key 2022 Achievements — Gaining Critical Mass
Key 2022 Achievements — Gaining Critical Mass January April May July May June July August September October April
Slide 6: Annamycin
Annamycin Next Generation Anthracycline Demonstrated to Be Non-Cardiotoxict Ability to overcome multi-drug resistance Organotrophic properties (e.g. >30x greater accumulation in lungs than doxorubicin) Potent topoisomerase-I! poison with a wider therapeutic window than doxorubicin? <10% incidence of
Slide 7: Annamycin: Phase 1b/2 Study for STS Lung Mets
Annamycin Ongoing Phase 2 Portion of 1b/2 Study for Treatment of STS Lung Mets US Multi-Center, Open-Label, Dose Escalation Study 25) Phase 2 subjects Phase 1b Concluded Phase 2 Recruitment Open RP2D determined to Decrease to 330 g/m? be 360 mg/m? from 360 g/m? Preliminary Phase 1b Data Showed No Ca
Slide 8: Annamycin: Second Phase 1b/2 Trial in Europe
Annamycin Second Phase 1b/2 Clinical Trial of Annamycin in STS Lung Mets with Pulmonary Metastases Investigator-Funded in Europe D a ar 28-day ick Rather than once every 21 day Subjects dosed 3 weeks as in the US trial Grant-funded clinical trial is led by para suiooina ces Prof. Piotr Rutkowski, MD
Slide 9: Annamycin: Phase 1/2 Study for R/R AML
Annamycin Phase 1/2 Study for Treatment of Relapsed or Refractory (R/R) AML EU Multi-Center, Open-Label, Dose Escalation Study 240 mg/m? 1, 2&3 with 21 days off Preclinical data Single-agent Preliminary RP2D established 1 Cytarabine fective vs Infusion days Primary Endpoint Met Pivoting to Phase 1/2
Slide 10: WP1122
WP1122 a Phase 1a Study COVID-19 Study Concluded First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Overlapping SAD and MAD Clinical Trial Determined MTD Daily Cumulative Dose of 32 mg/kg in Two Divided Doses for Seven Days Ongoing Effort to Identify Partner to Fund Further Advancement of
Slide 11: Multiple Milestones And Key Data Readouts
Multiple Milestones And Key Data Readouts Expected Before Year End 2022 and Into aaa) STS (US) STS (EU) AML ° ° 8 Phase 2 Initiate Commence Dosing in Phase Interim Data Phase 1b/2 1/2 Ara-C combination study WP1122/ —— — WP1 p20) Results from NIH- Potential funded animal study collaboration Bmorecuu
Slide 12: Q3 2022 Financial Highlights
Q3 2022 Financial Highlights R&D expense of $14.8 million and $11.2 million for the nine months ended September 30, 2022 and 2021 G&A expense of $8.7 million and $6.4 million for the nine months ended September 30, 2022 and 2021 The Company ended the quarter with $50.4 million of cash. Sufficient ca
Slide 13: Setting the Stage for a Breakthrough Year Ahead
Setting the Stage for a Breakthrough Year Ahead & eGzMOLECULIN 8 Annamycin Next generation non-cardiotoxic anthracycline demonstrating both safety and promising early activity across multiple clinical studies Second Lead Program Data to potentially support future cancer and anti-viral studies Pipeli
Slide 14: Bmorecuun
Bmorecuun
Slide 15: g
2 g